Protein measurement technology supplier BioScale has introduced a new ViBE software v3 at the Protein Engineering Summit (PEGS) conference in Boston, US.


Designed for use in GLP and drug development labs, the new software enables faster plate read times of one hour, lower reagent consumption, FDA 21 CFR Part 11 tools and LIMS connectivity.

BioScale commercial operations vice-president Christopher Silva said: "The new software allows customers to deploy the ViBE platform in phase 1 clinical studies and other GLP labs in drug development and QC.

"The ViBE platform, paired with our non-optical Acoustic Assays, overcomes limitations of traditional methods like ELISA or Western blot by providing a simple, highly sensitive method of measuring specific proteins in a complex sample, with walk-away automation."

According to Silva, the new software allows scientists to study immunologic interferences, pharmacokinetic profiling and toxicity as part of their IND program in the areas of oncology, CNS, cardiovascular and inflammation research.

Using the firm’s acoustic membrane microparticle (AMMP) technology, the ViBE platform helps in non-optical and acoustic protein measurement.

The platform includes 1, 2, 3 and 6-plate assay formats, which allow analysis of up to 576 samples per cartridge.

The firm’s acoustic assays are said to measure analyte concentration by determining changes in oscillation frequency caused by the binding of microparticles to the sensor surface.

Image: BioScale has designed new software v3 for use on ViBE platform to enhance productivity and cost-efficiency in drug development. Photo: courtesy of Stuart Miles/